Drug intelligence / Profile preview

[225Ac]Ac-Macropa-IgG

Development stage: Unknown
Lead developer: Ratio Therapeutics
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

[225Ac]Ac-Macropa-IgG is an untargeted radiopharmaceutical used as a control in preclinical studies for targeted alpha therapy. It consists of the alpha-emitting radioisotope Actinium-225 ([225Ac]) chelated by Macropa and conjugated to a non-targeting immunoglobulin G (IgG) antibody. In the provided context, it served as a control for [225Ac]Ac-Macropa-isatuximab, a targeted alpha therapy for hematological malignancies.

Targets

CA9 (Carbonic anhydrase IX)

Beyond the preview

Go deeper on [225Ac]Ac-Macropa-IgG.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on [225Ac]Ac-Macropa-IgG.

Explore the full profile